Somerset, N.J. – February 26, 2015 - Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has today announced several expanded capabilities within its European Clinical Supply Services network. The expansions have been implemented in response to increased customer demand for specialty clinical packaging, where the proportion of highly-potent or temperature-sensitive investigational medical products continues to increase.
At its Schorndorf, Germany, facility, Catalent tripled its frozen storage (-18°C) capacity and has added a second automated Inova® packaging line for pre-filled syringes, with capabilities including plunger-rod insertion, application of single panel labels, finger flanges, and safety device mounting. At its controlled substances facility in Deeside, UK, the company has expanded its clinical storage capacity with the addition of a third vault, bringing the combined controlled substance storage capacity to over 14,000 cubic feet. The Bathgate, UK facility’s cold storage capabilities have been updated to include a cryogenic storage service, suitable for stem cells, regenerative therapies and other clinical materials.
And finally, at Catalent’s primary packaging facility, in Bolton, UK, the company has installed two new energy-efficient chiller units that increase output capacity by more than 10%.
“As with our recent investments in our US capabilities, we are committed to offering comprehensive clinical supply solutions throughout our European network,” commented Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Catalent’s Clinical Supply Services business. “A key part of that commitment is ensuring that our facilities are well aligned with the current, emerging and future needs of our customers, as evidenced by our recent investments in Europe and the harmonization of key systems across all Catalent sites.”
The 60,000 sq. ft. Schorndorf facility offers primary and secondary packaging for oral dose solids and pre-filled syringes; cold, frozen and controlled drug clinical storage; and EU-GMP audit, importation, release and consulting services. The 125,000 sq. ft. Deeside facility provides comprehensive primary and secondary packaging services, with extensive capabilities in the cold storage of temperature-sensitive and controlled drug substances handling. The 141,000 sq. ft. Bathgate facility provides primary and secondary packaging services and returns and destruction management. The 61,000 sq. ft. Bolton facility offers state-of-the-art clinical supply services and is capable of supporting a range of primary and secondary packaging projects, from early stage clinical studies to specialty commercial packaging needs, including cold storage or highly-potent drugs handling. All four sites provide end-to-end clinical supply solutions that also include clinical supply management and comparator sourcing.
Inova® is a registered trademark of Optima Packaging Group GmbH.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.